Explore the vast range of titles available.

Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PPCI) accrues additional benefit of reducing myocardial infarct size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients. STEMI patients presenting within 12 hours and with a proximal coronary artery occlusion with Thrombolysis In Myocardial Infarction flow grade 0 were consented and randomized to either an intravenous bolus of potassium canrenoate, followed by oral spironolactone for 3 months or matching placebo. The primary endpoint was MI size by cardiovascular magnetic resonance at 3 months. Sixty-seven patients completed the study. There was no significant difference in the final MI size at 3 months between the 2 groups (placebo: 17 ± 11%, MRA: 16 ± 10%, P = .574). There was also no difference in acute MI size (26 ± 16% versus 23 ± 14%, P = .425) or myocardial salvage (26 ± 12% versus 24 ± 8%, P = .456). At follow-up, there was a trend towards an improvement in LVEF (placebo: 49 ± 8%, MRA: 54 ± 11%, P = .053), and the MRA group had significantly greater percentage decrease in LVEDV (mean difference: −12.2 (95% CI −20.3 to −4.4)%, P = .003) and LVESV (mean difference: −18.2 (95% CI −30.1 to −6.3)%, P = .003). This pilot study showed no benefit of MRA therapy in reducing MI size in STEMI patients when initiated prior to reperfusion, but there was an improvement in LV remodeling at 3 months. Adequately powered studies are warranted to confirm these findings.

Fractional flow reserve (FFR) assessment of remote arteries, in the context of a bystander chronic total occlusion (CTO), can lead to false positive results. Adenosine stress cardiovascular magnetic resonance (CMR) evaluates perfusion defects across the entire myocardium and may therefore be a reliable tool in the work-up of remote lesions in CTO patients. The IMPACT-CTO study investigated donor artery invasive physiology before, immediately post, and at 4 months following right coronary artery (RCA) CTO percutaneous coronary intervention (PCI). The aim of this subanalysis was to assess the concordance between baseline perfusion CMR and serial FFR evaluation of left anterior descending artery (LAD) ischemia in patients from the IMPACT-CTO study. Baseline adenosine stress CMR examinations from 26 patients were analyzed for qualitative evidence of LAD ischemia. The results were correlated with the serial LAD FFR measurements. The present findings demonstrated that before RCA CTO PCI, there was 62% agreement between perfusion CMR and FFR (ischemic threshold £ 0.8) in the assessment of LAD ischemia (k = 0.29; fair concordance). At 4 months after revascularization, there was 77% agreement (k = 0.52; moderate concordance) between the index CMR assessment of LAD ischemia and the follow-up LAD FFR. Concordance was improved at a LAD FFR ischemic threshold of £ 0.75. In this hypothesis generating study, baseline CMR assessment of LAD ischemia correlated better with the 4 months LAD FFR data (threshold £ 0.8) as compared to the FFR measurements taken prior to RCA CTO revascularization.

Percutaneous coronary intervention (PCI) for coronary chronic total occlusion (CTO) has been performed for the improvement of symptoms and quality of life in patients with stable angina. The ORBITA study demonstrated the role of the placebo effect in contemporary PCI in non-CTO chronic coronary syndromes. However, the benefit of CTO PCI beyond that of a placebo has not been demonstrated. The ORBITA-CTO pilot study will be a double-blind, placebo-controlled study of CTO PCI randomising patients who have: (1) been accepted by a CTO operator for PCI; (2) experienced symptoms due to a CTO; (3) evidence of ischaemia; (4) evidence of viability within the CTO territory; and (5) a J-CTO score ≤3. Patients will undergo medication optimisation that will ensure they are on at least a minimum amount of anti-anginals and complete questionnaires. Patients will record their symptoms on an app daily throughout the study. Patients will undergo randomisation procedures, including an overnight stay, and be discharged the following day. All anti-anginals will be stopped after randomisation and re-initiated on a patient-led basis during the 6-month follow-up period. At follow-up, patients will undergo repeat questionnaires and unblinding, with a further 2-week unblinded follow-up. The co-primary outcomes are feasibility (blinding) in this cohort and angina symptom score using an ordinal clinical outcome scale for angina. Secondary outcomes include changes in quality-of-life measures, Seattle Angina Questionnaire (SAQ), peak VO2, and anaerobic threshold on the cardiopulmonary exercise test. The feasibility of a placebo-controlled CTO PCI study will lead to future studies assessing efficacy. The impact of CTO PCI on angina measured using a novel daily symptom app may provide improved fidelity in assessing symptoms in patients with CTO's.

IntroductionCoronary wedge pressure (CWP) in STEMI is measured during coronary occlusion, with a distal pressure wire sensor, and can be used to assess the coronary flow pressure index (CFPI = CWP/aortic pressure). Its clinical significance in STEMI, however, remains controversial, with conflicting reports on its predictive value for microvascular obstruction (MVO). Early studies suggested that a higher CFPI correlated with better left ventricular (LV) recovery, while others linked elevated CWP to worse outcomes, including increased LV remodelling and reduced ejection fraction. Given these inconsistencies, we examined a large cohort of anterior STEMI patients with recorded CWP to determine its relationship with MVO as assessed by cardiac MRI (CMR).MethodsThis retrospective analysis evaluated a subset of patients from the EUROICE trial (NCT03447834), a multicentre RCT enrolling 200 anterior STEMI patients with occluded proximal/mid-LAD. Patients were randomised 1:1 to selective intracoronary hypothermia (SIH) or standard primary PCI. This sub-analysis focused on the SIH group, assessing coronary wedge pressure using over-the-wire balloon occlusion. We calculated systolic, mean, and diastolic wedge pressures, CFPI, and balloon deflation time. These parameters were correlated with MVO on CMR at 2–7 days.ResultsOf 82 SIH patients, 73 had interpretable coronary wedge pressure data. Linear regression showed no significant correlation between balloon deflation time (pressure equalisation) and MVO severity (r=-0.209, p=0.085). Similarly, CFPI demonstrated a weak negative correlation with%MVO on CMR (r=-0.12, p=0.37). Systolic, diastolic, and mean coronary wedge pressures also showed slight negative correlations with%MVO (r = -0.21, r = -0.16, and r = -0.22, respectively).Abstract 2-005 Figure 1Abstract 2-005 Figure 2ConclusionThis study represents the largest early presenting anterior STEMI cohort with recorded coronary wedge pressure. We found no significant relationship between CFPI and MVO. Currently the index of microvascular resistance (IMR) remains the gold standard for assessing MVO, further refinement of risk stratification tools is necessary to better predict and mitigate adverse outcomes in STEMI patients.

Dual antiplatelet therapy (DAPT) is widely used for secondary prevention following acute coronary syndrome and percutaneous coronary intervention (PCI). Gastrointestinal (GI) bleeding is a known complication of DAPT, typically due to peptic ulcer disease or gastritis. However, oesophageal haematoma is a rare and under-recognised cause of upper gastrointestinal bleeding (UGIB) in this setting. We present a case of a 65-year-old woman who attended an Accident and Emergency Department with typical central chest pain, vomiting, and haematemesis, six months after undergoing PCI and commencing DAPT. Initial investigations raised suspicion for acute coronary syndrome as she presented with chest pain, but coexistent persistent gastrointestinal symptoms, including ongoing haematemesis and vomiting, prompted further evaluation. Oesophagogastroduodenoscopy revealed a large oesophageal haematoma at 20 cm (from incisors) extending to the gastroesophageal junction, approximately 10 cm in length. Contrast-enhanced CT confirmed a non-perforated lesion without mediastinal air. Clopidogrel was discontinued, and the patient was managed conservatively with intravenous proton pump inhibitors (PPIs) for 72 hours. Follow-up endoscopy at two months demonstrated complete resolution of the haematoma. This case illustrates an uncommon but important complication of antiplatelet therapy and reinforces the need for diagnostic vigilance in patients presenting with atypical gastrointestinal symptoms while on DAPT. Individualised management and multidisciplinary input are key to achieving optimal outcomes.

BackgroundThere is strong evidence of FFR guided treatment in multi-vessel disease. Multi-vessel disease is present in up to 66% of patients with CTO in a large registry analysis. The presence of a concomitant CTO may influence the FFR measurement in donor vessel as suggested in previous studies and reports. This has an important implication on clinical decision making for complete revascularisation in patients with chronic total occlusions. There is a growing interest on the influence of collateral circulation, flow, amount of myocardium supplied by donor artery to a CTO and the impact of CTO revascularisation on donor vessel pressure-derived indices. We sought to investigate the physiological impact of CTO recanalisation on donor vessel pressure-derived indices.MethodsThe study participants were patients with angina who had RCA CTO. 34 out of 40 consecutive patients underwent successful PCI to RCA CTOs during the study period were included in the analysis. Coronary pressure-derived indices (resting Pd/Pa, iFR and FFR) were measured pre and post successful RCA CTO PCI in donor vessels. Donor vessel characteristics were graded using the Rentrop and colloateral connexion grading classification.ResultsThe mean age was 61.76 years. The mean estimated CTO duration was 238.72 weeks and CTO length was 32.44 mm. 31 patients had ischaemia and or viability in the RCA territory assessed with cardiac MRI.LAD was the predominant donor vessel in 30 patients and LCX was the minor donor vessel in 4 patients. Percent stenosis on QCA in the predominant and minor donor vessel were 41.43% and 35.05% respectively. The angiographic details are as outlined in table 1. The mean resting Pd/Pa, iFR and FFR pre and post RCA CTO PCI in major donor vessel were (0.891, 0.858, 0.759) and (0.903, 0.882, 0.746) respectively. iFR in the major donor vessel increased from 0.858 to 0.882 (difference, 0.02412 (0.00573 to 0.04250); p=0.012). There were no significant difference in resting Pd/Pa and FFR pre and post CTO PCI (p=0.109 and p=0.388 respectively).The mean resting Pd/Pa, iFR and FFR pre and post RCA CTO PCI in minor donor vessel were (0.982, 0.969, 0.894) and (0.985, 0.979, 0.885) respectively. There were no significant difference in resting Pd/Pa, iFR and FFR pre and post CTO PCI in minor donor vessel (p=0.534, p=0.152, p=0.183 respectively).The mean collateral FFR was 0.310. The mean total ischaemic burden on baseline cardiac MRI in RCA territory was 12.6%.ConclusionSuccessful recanalisation of a RCA CTO results in increase in iFR but no significant difference was seen in resting Pd/Pa and FFR pre-RCA CTO PCI and immediately post recanalisation in predominant donor vessel. Complete collateral regression was not observed in all patients immediately post RCA CTO PCI and this may account for the non-significant change in FFR values.Abstract 24 Table 1Angiographic Characteristics

BackgroundThere is strong evidence of FFR guided treatment in multi-vessel disease. The presence of a concomitant CTO may influence the FFR measurement in donor vessel as suggested in previous studies and reports. This has an important implication on clinical decision making for complete revascularisation in patients with chronic total occlusion. We sought to investigate the influence of collateral regression after successful CTO recanalisation on donor vessel pressure-derived indices.MethodsThe study participants were patients with angina who had RCA CTO. 28 out of 34 consecutive patients underwent successful PCI to RCA CTOs during the study period and completed the follow study (at 3 months post CTO PCI) were included in this analysis. Coronary pressure-derived indices (resting PD/PA, iFR and FFR) were measured pre and post successful RCA CTO PCI in donor vessels and at follow up procedures.ResultsThe mean age was 62.38 years. The mean estimated CTO duration was 238.72 weeks and CTO length was 32.44 mm. 25 patients had ischaemia and or viability in the RCA territory assessed with cardiac MRI. LAD was the major donor vessel in 24 patients and LCX was the minor donor vessel in 4 patients. Percent stenosis on QCA in the major and minor donor vessel were 40.6% and 35.1% respectively. The mean resting Pd/Pa, iFR and FFR pre and post RCA CTO PCI and at follow-up procedures in major donor vessel were (0.893, 0.862, 0.764), (0.907, 0.886, 0.753) and (0.918, 0.901, 0.787) respectively. The mean resting Pd/Pa, iFR and FFR pre and post RCA CTO PCI and at follow-up procedures in minor donor vessel were (0.979, 0.966, 0.890), (0.983, 0.979, 0.880) and (0.981, 0.974, 0.898) respectively. The changes in coronary pressure-derived indices pre and post RCA CTO PCI and at follow up procedures are summarised in table 1. In major donor vessel, there was significant changes in the difference between follow up and pre-CTO PCI values for Pd/Pa, iFR and FFR values (p values 0.006, 0.003 and 0.047 respectively). There was also significant change in the difference between follow up and post-CTO PCI FFR value (P value 0.002). FFR collateral reduced significantly at follow-up (p value 0.000).ConclusionSuccessful recanalisation of a RCA CTO results in increase in major donor vessel coronary pressure-derived indices at follow up procedure associated with the regression of collateral function. In patients with multi-vessel disease, the expected change and the optimal timing to perform PCI in donor vessel should be considered when planning multi-vessel revascularisation in this setting.Abstract 23 Table 1Coronary pressure-derived indices pre and post RCA CTO PCI and at follow up procedures (FU:Follow-up, PCI:Percutaneous Coronary Intervention, FFR: Fractional Flow Reserve, CTO: Chronic Total Occlusion)

BackgroundPrimary PCI is the gold standard treatment for acute STEMI, but reperfusion injury limits its beneficial effect on infarct size (IS). In experimental studies, therapeutic hypothermia (HT) consistently reduces IS caused by reperfusion injury, but translation into clinical practice remains a challenge. The purpose of our study (part of COOL AMI EU study) was to assess the feasibility of integrating pre-reperfusion HT using an intravascular temperature management system (Thermogard XP, ZOLL, USA) into routine clinical practice without a significant delay in door-to-balloon (DTB) time.MethodsPatients with STEMI presenting within 6 h of symptoms onset and planned for PPCI were prospectively enrolled. TH was implemented by intravenous infusion (IV) of cold saline and a heat-exchange balloon catheter inserted via the right femoral vein. Oral buspirone and IV pethidine were used to control shivering. HT was continued for a total time of 3 h, followed by passive rewarming.Results18 patients were successfully recruited. The average age was 60.3 years and 94.4% were male. The DTB time was 40.6 min. There was an increase of 3.6 min compared with the mean DTB time of 37 min for patients who underwent PPCI and did not received HT. Mean temperature at reperfusion was 34.4 °C. There were no adverse events related to the use of the heat-exchange catheter or the implementation of hypothermia.ConclusionHypothermia is feasible and safe in STEMI patients without significant delay in door-to-balloon time.

Maternal red blood cell (RBC) alloimmunization may lead to production of harmful antibodies that result in hemolytic disease of fetus and newborn (HDFN). There is insufficient data on the prevalence of HDFN due to RBC alloantibodies in the Malay neonatal population. The aim of this study was to determine the incidence of HDFN in the Malay neonatal population due to clinically significant RBC alloantibodies. A cross sectional study was conducted in Transfusion Medicine Unit, Hospital Universitiy Sains Malaysia over one year period from January to December 2009. A total of 5163 Malay pregnant women who attended labor room for delivery were collected and analyzed prospectively. The blood samples were subjected to the standard immunohematological procedure for RBC antibody screening and identification using reagents of Diamed-ID Gel microtyping system. All the newborns with RBC alloantibody were investigated for the evidence of HDFN. Thirty (0.58%) women were found to have clinically significant RBC alloantibodies. Most of the alloantibodies belonged to Rhesus (Rh) system (56.7%) where anti-E (33.3%) was the most common followed by anti-D (10.0%). Rh antibodies were the main cause of HDFN in fourteen (0.27%) neonates. Anti-D and anti-c were identified to cause moderate to very severe HDFN. With the low prevalence of clinically significant RBC alloantibodies and HDFN, routine antenatal antibody screening practice may not be advised as a routine practice at present, preferably reserved for those women of RhD negative or with history of HDFN, significantly of those attributed to anti-c.